NRXP · NRX Pharmaceuticals, Inc.
$3.67
+0.22 (+6.38%)
At close · Aug 25
Going-concern doubt
— flagged Aug 14, 2026
Substantial doubt about the company's ability to continue as a going concern.
“As such, the Company has concluded that substantial doubt exists regarding the Company's ability to continue as a going concern for a period of at least twelve months from the date of issuance of these consolidated financial statements.”View the 10-Q filed Aug 14, 2026
Market Cap
$152.40M
Shares
43.30M
The company's filings as submitted to the SEC's EDGAR system — 10-K, 10-Q, 8-K, proxy statements and more — listed most recent first.
| Type | Filing Date | Period | Open |
|---|---|---|---|
| 8-K | 2026-08-17 | — | |
| 10-Q | 2026-08-14 | 2026-06-30 | |
| 8-K | 2026-08-07 | — | |
| 8-K | 2026-07-22 | 2026-07-21 | |
| 8-K | 2026-06-04 | 2026-06-03 | |
| 8-K | 2026-06-02 | — | |
| Investor Event Transcript | 2026-05-18 | 2026-06-30 | |
| 10-Q | 2026-05-15 | 2026-03-31 | |
| Investor Event Transcript | 2026-03-31 | — | |
| 8-K | 2026-03-24 | 2026-03-23 | |
| 10-K | 2026-03-23 | 2025-12-31 | |
| DEF 14A | 2026-02-23 | 2026-03-23 | |
| 8-K | 2026-02-17 | — | |
| 8-K | 2026-02-17 | — | |
| 8-K | 2026-02-02 | 2026-01-27 | |
| 8-K | 2026-01-16 | 2026-01-12 | |
| Investor Event Transcript | 2025-12-31 | — | |
| 8-K | 2025-12-29 | 2025-12-18 | |
| 8-K | 2025-11-26 | 2025-11-20 | |
| 8-K/A | 2025-11-21 | 2025-09-08 | |
| 10-Q | 2025-11-14 | 2025-09-30 | |
| 8-K | 2025-10-23 | 2025-10-17 | |
| 8-K | 2025-09-26 | 2025-09-24 | |
| 8-K | 2025-09-12 | 2025-09-08 | |
| 8-K | 2025-09-08 | 2025-09-02 | |
| 10-Q | 2025-08-18 | 2025-06-30 | |
| 8-K | 2025-08-18 | — | |
| 8-K | 2025-08-15 | 2025-08-11 | |
| 8-K | 2025-06-09 | 2025-06-05 | |
| 8-K | 2025-05-21 | 2025-05-15 | |
| 10-Q | 2025-05-15 | 2025-03-31 | |
| 8-K | 2025-05-13 | — | |
| 10-K/A | 2025-04-30 | 2024-12-31 | |
| 8-K | 2025-04-17 | — | |
| 8-K | 2025-03-21 | 2025-03-17 | |
| 10-K | 2025-03-14 | 2024-12-31 | |
| 8-K | 2025-02-03 | 2025-01-28 | |
| 8-K | 2025-01-29 | 2025-01-27 | |
| 8-K | 2025-01-22 | 2025-01-15 | |
| 8-K | 2025-01-14 | 2025-01-07 | |
| 8-K | 2025-01-10 | 2025-01-06 | |
| 8-K | 2024-11-20 | 2024-11-18 | |
| 8-K | 2024-11-15 | 2024-11-14 | |
| 10-Q | 2024-11-14 | 2024-09-30 | |
| 8-K | 2024-10-31 | 2024-10-30 | |
| 8-K | 2024-10-15 | 2024-10-10 | |
| 8-K | 2024-10-11 | 2024-10-07 | |
| DEF 14A | 2024-09-05 | 2024-10-08 | |
| 8-K | 2024-08-20 | 2024-08-14 | |
| 8-K | 2024-08-15 | 2024-08-14 |
Showing 1–50 of 169 filings
Key facts
CIK
1719406
CUSIP
629444209
13F (30d)
46 filings
46 filers
Visit website
Investor relations